- Home
- LSH vs PMCB Comparison
LSH vs PMCB Comparison
Compare LSH & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSH
- PMCB
- Stock Information
- Founded
- LSH 2018
- PMCB 1996
- Country
- LSH United States
- PMCB United States
- Employees
- LSH N/A
- PMCB N/A
- Industry
- LSH
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSH
- PMCB Health Care
- Exchange
- LSH NYSE
- PMCB Nasdaq
- Market Cap
- LSH 6.6M
- PMCB 7.3M
- IPO Year
- LSH 2024
- PMCB N/A
- Fundamental
- Price
- LSH $0.92
- PMCB $1.12
- Analyst Decision
- LSH
- PMCB
- Analyst Count
- LSH 0
- PMCB 0
- Target Price
- LSH N/A
- PMCB N/A
- AVG Volume (30 Days)
- LSH 14.2K
- PMCB 12.4K
- Earning Date
- LSH 08-01-2025
- PMCB 08-12-2025
- Dividend Yield
- LSH N/A
- PMCB N/A
- EPS Growth
- LSH N/A
- PMCB N/A
- EPS
- LSH N/A
- PMCB 1.29
- Revenue
- LSH $16,270,095.00
- PMCB N/A
- Revenue This Year
- LSH N/A
- PMCB N/A
- Revenue Next Year
- LSH N/A
- PMCB N/A
- P/E Ratio
- LSH N/A
- PMCB $0.85
- Revenue Growth
- LSH N/A
- PMCB N/A
- 52 Week Low
- LSH $0.82
- PMCB $1.00
- 52 Week High
- LSH $4.34
- PMCB $2.42
- Technical
- Relative Strength Index (RSI)
- LSH N/A
- PMCB 52.20
- Support Level
- LSH N/A
- PMCB $1.06
- Resistance Level
- LSH N/A
- PMCB $1.15
- Average True Range (ATR)
- LSH 0.00
- PMCB 0.05
- MACD
- LSH 0.00
- PMCB 0.01
- Stochastic Oscillator
- LSH 0.00
- PMCB 64.40
About LSH LAKESIDE HOLDING LTD
Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.